Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies

Area of Science:

• Oncology
• Hematology
• Pharmacology

Background:

• Relapsed/refractory lymphoid malignancies present significant therapeutic challenges.
• Current treatment selection strategies are often ineffective for these aggressive cancers.

Purpose of the Study:

• To evaluate the feasibility of high-throughput ex vivo drug profiling for guiding treatment selection in lymphoid malignancies.
• To identify potential therapeutic vulnerabilities in relapsed/refractory lymphoid cancers.

Main Methods:

• Conducted high-throughput ex vivo drug sensitivity and resistance testing on patient-derived tumor cells.
• Analyzed drug responses across various lymphoid malignancy subtypes.
• Correlated drug sensitivity with specific molecular aberrations, such as p53 alterations.

Main Results:

• Successful drug profiling was achieved in 22 out of 26 patients.
• Demonstrated broad ex vivo resistance to conventional chemotherapeutic agents.
• Observed significant sensitivity to BH3 mimetics.
• Identified increased sensitivity to dasatinib and PI3K inhibitors in p53-aberrant samples.

Conclusions:

• Functional precision medicine pipelines are feasible for lymphoid malignancies.
• Ex vivo drug profiling can uncover actionable therapeutic vulnerabilities.
• BH3 mimetics, dasatinib, and PI3K inhibitors represent promising avenues for further clinical investigation.